Roberts, Glore & Co’s Charles River Laboratories CRL Stock Holding History

Roberts, Glore & Co’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,223	Closed	-$964K	–	203
2024 Q4	$964K	Sell	5,223 -63	-1%	-$12.1K	0.29%	81
2024 Q3	$1.04M	Sell	5,286 -115	-2%	-$23.9K	0.3%	82
2024 Q2	$1.12M	Sell	5,401 -5	-0.1%	-$1.13K	0.34%	75
2024 Q1	$1.46M	Sell	5,406 -75	-1%	-$17.9K	0.44%	63
2023 Q4	$1.3M	Buy	5,481 +578	+12%	+$114K	0.4%	67
2023 Q3	$961K	Sell	4,903 -15	-0.3%	-$3.08K	0.32%	79
2023 Q2	$1.03M	Buy	4,918 +1,198	+32%	+$238K	0.33%	73
2023 Q1	$751K	Buy	3,720 +2,580	+226%	+$585K	0.25%	86
2022 Q4	$248K	Buy	+1,140	New	+$249K	0.09%	162

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Roberts, Glore & Co's CRL Position: Q1 2025 in Review

Roberts, Glore & Co sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 5,223 shares — an estimated $964K sold.

Roberts, Glore & Co first reported a position in CRL in Q4 2022 and held it in 9 quarters. The position peaked at $1.46M in Q1 2024. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

Roberts, Glore & Co reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
Roberts, Glore & Co sold 5,223 Charles River Laboratories shares in Q1 2025, an estimated $964K.
Roberts, Glore & Co first reported a position in Charles River Laboratories in Q4 2022 and held it in 9 quarters.
Roberts, Glore & Co's Charles River Laboratories position peaked at $1.46M in Q1 2024.
561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Roberts, Glore & Co's 13F filing for Q1 2025, filed 9 May 2025.